Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Interest Income : HK$6 Mil (TTM As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Biocytogen Pharmaceuticals (Beijing) Co's interest income for the six months ended in Dec. 2024 was HK$3 Mil. Its interest income for the trailing twelve months (TTM) ended in Dec. 2024 was HK$6 Mil.

Biocytogen Pharmaceuticals (Beijing) Co Interest Income Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Interest Income Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Income

6.82

15.31

2.42

11.11

6.29

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Interest Income	Get a 7-Day Free Trial				1.50	6.02	5.09	3.71	2.61

Biocytogen Pharmaceuticals (Beijing) Co Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$6 Mil.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » Interest Income

Comparable Companies

Traded in Other Exchanges

I54:Germany

Address

12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN

Website

https://www.biocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Executives

Wei Ke Xiang Gang Jing Mao You Xian Gong Si	2101 Beneficial owner
Bvcf Realization Fund, L.p.	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si	2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Yang Zhi	2201 Interest of corporation controlled by you
Innoveda Medtech, Ltd.	2201 Interest of corporation controlled by you
Ni Jian
Bvcf Realization Fund Gp, Ltd.	2201 Interest of corporation controlled by you
Bioveda China Fund Ii Rmb, Limited	2101 Beneficial owner
Cmbi Private Equity Series Spc	2201 Interest of corporation controlled by you
Cmb International Private Investment Limited	2201 Interest of corporation controlled by you

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines